CJC-1295 & Ipamorelin

It's a peptide blend combining a long-acting GHRH analog (CJC-1295) with a selective GHRP (Ipamorelin) to stimulate the body's own pulsatile growth hormone release. The two peptides are commonly compounded together because they act synergistically on different pituitary receptors.

CJC-1295 amplifies and extends natural GH pulses via the GHRH receptor, while Ipamorelin triggers an additional clean GH pulse via the ghrelin receptor. Together they produce more GH than either peptide alone — clinical pharmacology data has documented up to a 5× synergistic increase compared to single-agent dosing.

HGH replaces growth hormone directly with a constant external supply, which suppresses your body's own production. CJC-1295 + Ipamorelin instead signals your body to make its own GH in a natural pulsatile rhythm, preserving feedback loops and avoiding the suppression risk of long-term exogenous HGH.

Sermorelin is a short-acting GHRH analog used alone. CJC-1295 + Ipamorelin combines a longer-acting GHRH analog with a selective GHRP, producing a synergistic GH pulse that is measurably stronger than GHRH alone. Many patients on Sermorelin who plateau move to this blend for the additional dual-receptor effect.

MK-677 is an oral 24-hour ghrelin agonist that raises GH continuously and tends to spike appetite, water retention, and cortisol. Ipamorelin is selective and pulsatile, with no appetite or cortisol effect — preserving the natural rhythm of GH release that the body is built around.

Sleep improvements often appear within the first 1–2 weeks. Recovery and energy follow within 4–6 weeks. Visible body composition and skin/hair changes typically peak around 8–12 weeks of consistent dosing.

The most commonly reported are transient flushing or warmth shortly after injection, mild injection-site redness, dry mouth, mild nausea, and occasional appetite or vivid-dream changes. Side effects are generally mild and dose-dependent, and most resolve within the first few weeks of therapy.

A small subcutaneous injection, typically dosed five nights a week (Monday–Friday) before bed (around 9 PM is ideal) on an empty stomach. This aligns the dose with your body's natural overnight GH pulse and gives your pituitary a weekend off to prevent receptor desensitization.

The two concentrations let your provider tailor your effective dose without forcing you to draw awkward injection volumes. The 1.5 mg/ml in a 6 ml vial yields 9 mg total; the 2 mg/ml in a 5 ml vial yields 10 mg total. Your prescriber will recommend the option best matched to your protocol and goals.

Neither CJC-1295 nor Ipamorelin is FDA-approved as a finished drug. They are prescribed and compounded by licensed pharmacies under physician supervision when clinically appropriate.

Anyone pregnant, breastfeeding, with active or prior cancer, with active diabetic retinopathy, or with known pituitary disorders should avoid it. Always disclose your full medical history to your prescriber so they can evaluate safety.

GH-modulating medications, corticosteroids, and certain hormone therapies can interact with this blend. Share all current medications with your provider before starting so they can determine safety and adjust the protocol as needed.

Keep unreconstituted vials refrigerated at 36–46°F (2–8°C) and protected from light. Once reconstituted with bacteriostatic water, store in the fridge and use within the period your pharmacy specifies. Do not freeze.

GH levels return to your personal baseline after stopping; the blend does not permanently shut down or upregulate your pituitary. Most people cycle on and off under provider guidance — there is no withdrawal or rebound effect.